Physician
Kentucky Pain Management Services
Kentucky Pain Management Services was paid $3.46M by Medicaid between Jan 2018 and Dec 2024, across 28 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 55% of everything it billed.
33Billing provider infoKENTUCKY PAIN MANAGEMENT SERVICES
HAZARD, KY 41701
HAZARD, KY 41701
33aNPI1376692657assigned 01/09/2007
33bProvider typePain Medicine Physician
28Total paid$3.46M
24GClaims181,181
24DCodes billed28
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,242 | $1.23M | |
| 2019 | 43,766 | $1.04M | |
| 2020 | 22,207 | $302K | |
| 2021 | 24,855 | $202K | |
| 2022 | 23,692 | $225K | |
| 2023 | 13,382 | $237K | |
| 2024incomplete | 9,037 | $212K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 55% | 67,894 | 52,107 | $1.89M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 13% | 24,534 | 20,964 | $450K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 30,275 | 21,390 | $379K |
| 27096 | 8.1% | 1,157 | 966 | $279K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 4.1% | 2,868 | 2,251 | $141K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.5% | 2,467 | 1,959 | $122K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.1% | 5,224 | 3,593 | $73K |
| 72131 | 1.1% | 1,027 | 720 | $37K | |
| 99243 | <1% | 364 | 349 | $31K | |
| 64493 | <1% | 95 | 84 | $9K | |
| 62323 | <1% | 70 | 59 | $8K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,023 | 891 | $7K |
16 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,843 | $6K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,477 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 156 | $6K |
| 20552 | <1% | 184 | $5K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 41 | $3K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 204 | $2K |
| 72192 | <1% | 244 | $2K | |
| 72128 | <1% | 43 | $440.70 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 424 | $385.64 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 26 | $132.36 |
| G9583 | Patients prescribed opiates for longer than six weeks | <1% | 8,137 | $8.46 |
| J3490 | Unclassified drugs | <1% | 204 | $4.82 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 8,240 | $1.55 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 5,012 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 11,229 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 6,719 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMULLINS, PHILLIP (CEO)
| Provider | Location | Paid |
|---|---|---|
| Kentucky Primary Medical Services LLC | Hazard, KY | $27K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.